University of Missouri College of Veterinary Medicine
University / teaching hospital
5 current cancer treatment or research opportunities
About Missouri veterinary oncology
Missouri's veterinary hospital brings medical oncology, cancer surgery and radiation therapy into one program. Its clinicians work with university cancer scientists to test new treatments while also providing standard care for dogs and cats.
Cancer types currently listedLymphoma, Osteosarcoma, Primary Lung Tumor
Where visits take placeUniversity of Missouri Veterinary Health Center, 900 E Campus Dr, Columbia, MO 65211
Current options at University of Missouri College of Veterinary Medicine
Open an option to see who may qualify, locations, costs or coverage, contact details and the official source.
Timing of carboplatin chemotherapy after amputation for canine osteosarcoma
University of Missouri Veterinary Health Center · USA
Currently enrolling
What is being offered: Current live Missouri oncology roster explicitly lists 'Evaluation of Timing of Carboplatin Chemotherapy post Amputation for Osteosarcoma.' Eligible dogs have an untreated bone tumor with cytologic sarcoma and positive ALP staining, no lung metastasis and no prior treatment; they must undergo complete amputation followed by six carboplatin doses. Carboplatin starts the day after surgery or immediately before discharge, with follow-up until metastasis. This is an interventional timing study, not merely observational.
Who may qualify: Confirmed cancer diagnosis required; No metastasis; Planned amputation and chemo
May not qualify if: Prior local radiation; Prior immunotherapy
Costs / coverage: The study covers chest radiographs and CBC/chemistry at the first chemotherapy visit. Owners are responsible for screening diagnostics, amputation and all six carboplatin treatments.
Contact: Oncology Clinical Trials Service 573-882-7821; muoncology@missouri.edu
Location
University of Missouri Veterinary Health Center, 900 E Campus Dr, Columbia, MO 65211
BI705564 oral BTK inhibitor for newly diagnosed canine B-cell lymphoma
Multicenter — University of Missouri + CASE / BI 705564 field trial · USA
Currently enrolling
What is being offered: Investigational oral BTK inhibitor BI705564
Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 10; Max weight kg: 50; Measurable; Min age years exclusive: 1; Peripheral bcell lymphoma stage ii to iv
Costs / coverage: 🟢 Fully funded after enrollment. Screening bloodwork, urinalysis, chest X-rays, abdominal ultrasound, flow cytometry and the IDEXX Cancer Dx Panel are covered; once enrolled, the study is fully funded.
Whole-abdomen radiation followed by COP/doxorubicin for feline high-grade gastrointestinal lymphoma
University of Missouri Veterinary Health Center · USA
Currently enrolling — University of Missouri Veterinary Health Center
What is being offered: Whole-abdomen radiation therapy followed by COP/doxorubicin chemotherapy
Who may qualify: Confirmed cancer diagnosis required; Planned radiation; Planned chemo; High grade abdominal gi lymphoma; Felv fiv negative
May not qualify if: Prior chemo; Current chemo; Small cell lymphoma; Severe systemic disease
Costs / coverage: Partially funded. The study covers whole-abdomen radiation and provides a $1,000 credit for care at the VHC after radiation is completed. Published information does not specify screening, COP/doxorubicin chemotherapy, other care or travel coverage; confirm these costs with the study team.
Fully funded CAR-T cell therapy trial for canine B-cell lymphoma
LEAH Labs / University of Minnesota / Ohio State University / University of Missouri · USA
Missouri enrolling per current institutional protocol; Ohio State enrolling per sponsor with local slot to confirm; Minnesota on hold
What is being offered: One LEAH CAR-T protocol with site-specific cohorts. On October16 the current Missouri study-specific invitation and fresh Web read both explicitly confirm enrolling dogs with spontaneous CD20+ large-cell B-cell lymphoma; the older cached Missouri ON HOLD version is superseded. Missouri includes naive and relapsed patients, >10kg, clinically well, no primary GI or lung involvement, investigator bloodwork clearance, no Apoquel/mycophenolate/cyclosporine/azathioprine and at least72hours off prednisone. It combines lymphodepleting chemotherapy and xenogeneic CAR-T; at least seven visits over21days then longer follow-up. Minnesota current individual protocol remains On hold; its10-50kg and48hour rules must not be generalized to Missouri. Ohio remains enrolling per sponsor; its current institutional index does not name this protocol, so confirm the Ohio slot and local criteria before travel. Missouri-specific eligibility/funding do not establish Ohio or Minnesota terms.
Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned chemo
Costs / coverage: Missouri: study-related initial staging, treatment and rechecks covered; up to$4000 for adverse events and a$2000 stipend for future/additional VHC treatment upon completion. Sponsor describes Ohio enrollment as fully funded; confirm the current Ohio coverage and slot. Minnesota is on hold; its historical stipend/criteria are not generalized to other sites.
Contact: LEAH Labs — info@leahlabs.com; enrollment request form on the official site
Participating locations
The Ohio State University Veterinary Medical Center, 601 Vernon L Tharp St, Columbus, OH 43210
University of Missouri Veterinary Health Center, 900 E Campus Dr, Columbia, MO 65211
A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.
Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.
